I'm Back to Buy More Extendicare

Before you go, we thought you'd like these...
Before you go close icon

Yes, I've been buying a lot of Extendicare in my Special Situations portfolio. The stock comprises well over 30% of the portfolio, but I'm back to add to the position. The recent dip in the stock price in the face of an imminent, value-unlocking catalyst is just silly.

The situation is the same as before. Extendicare is selling its American unit, and is actively involved in negotiations with a buyer. It's cleared up an investigation with the U.S. government that had prevented a sale before. The resolution consists of a $38 million penalty and ongoing compliance costs of $1.5 million to $3.5 million annually for five years. Most importantly, the American unit retains its ability to participate in government health care programs. In my article from early last month, you can read further details of the resolution.

But despite the imminence of a deal, the stock continues to languish as impatient investors hit the exits. And guess what? Even without a deal to sell the American unit, the company has committed to divest the business, with a spinoff as the most likely outcome. Any split of the business here will force the market to see the value in the American unit, which it is currently drastically underestimating.

For more on Extendicare, follow me on Twitter: @TMFRoyal. And check out my dedicated discussion board. If the stock continues to drop from here without some kind of fundamental change, I expect that I will continue to buy more.

Foolish takeaway
My Special Situations portfolio is buying more Extendicare, adding about $2,000 - or about 2% of the portfolio - to my position. The stock already comprises over 30% of my holdings, but the low downside and the potential for significant upside here looks just too attractive to pass up.

Apple Watch revealed: The real winner is inside
Apple recently revealed the product of its secret-development "dream team" -- Apple Watch. The secret is out, and some early viewers are claiming its everyday impact could trump the iPod, iPhone, and the iPad. In fact, ABI Research predicts 485 million of this type of device will be sold per year. But one small company makes Apple's gadget possible. And its stock price has nearly unlimited room to run for early-in-the-know investors. To be one of them, and see where the real money is to be made, just click here!

The article I'm Back to Buy More Extendicare originally appeared on Fool.com.

Jim Royal owns stock in Extendicare. The Motley Fool owns shares of Extendicare. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

People are Reading